TY - JOUR
T1 - Biobank establishment and sample management in the tohoku medical megabank project
AU - Tohoku Medical Megabank Project Study Group
AU - Minegishi, Naoko
AU - Nishijima, Ichiko
AU - Nobukuni, Takahiro
AU - Kudo, Hisaaki
AU - Ishida, Noriko
AU - Terakawa, Takahiro
AU - Kumada, Kazuki
AU - Yamashita, Riu
AU - Katsuoka, Fumiki
AU - Ogishima, Soichi
AU - Suzuki, Kichiya
AU - Sasaki, Makoto
AU - Satoh, Mamoru
AU - Yamamoto, Masayuki
N1 - Funding Information:
Fig. 1. Schematic of Tohoku Medical Megabank (TMM) Project administration. The TMM biobank is a public biobank supported by the Japan Agency for Medical Research and Development (AMED) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The operation of the TMM biobank is overseen by the Ethical, Legal and Social Issues (ELSI) Committee, Advisory Board, and Research Ethics Committee (Ethics Committee). Applications from researchers are reviewed by the Sample and Data Access Committee, which comprises specialists in various fields not only from TMM but also from third-party institutions. After the applications are approved, the biobank provides the requested samples and data according to the material transfer agreements (MTAs).
Funding Information:
budget from the Great East Japan Earthquake; the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); and the Japan Agency for Medical Research and Development (AMED) (Fig. 1). The TMM Project is organized by the Ethical, Legal and Social Issues (ELSI) Committee and Advisory Board as well as the Research Ethics Committee, which comprises experts both inside and outside the organization.
Publisher Copyright:
© 2019 Tohoku University Medical Press.
PY - 2019
Y1 - 2019
N2 - The Tohoku Medical Megabank biobank (TMM biobank) is the first major population-based biobank established in Japan. The TMM biobank was established based on two population cohorts and is a reconstruction program from the Great East Japan Earthquake and Tsunami of 2011. The biobank stores more than 3.4 million tubes of biospecimens and associated health and analytic data obtained from approximately 150,000 TMM cohort participants between May 2013 and December 2018, and the TMM biobank currently shares high-quality specimens and data. Various biospecimens, including peripheral and cord blood mononuclear cells, buffy coat, plasma, serum, urine, breast milk and saliva have been collected in the TMM biobank. To minimize human error and maintain the quality of data and specimens, we have been utilizing laboratory information management system into various biobank procedures from registration to storage with various automation systems, such as liquid dispensing, DNA extraction and their storage. The biobank procedures for the quality management system (ISO 9001:2015) and information security management system (ISO 27001:2013) are certified by the International Organization for Standardization. The quality of our biobank samples fulfills the pre-analytical requirements for researchers conducting nextgeneration whole genome sequencing, DNA array analyses, proteomics, metabolomics, etc. We established analytical centers to conduct standard genomic and multiomic analyses in-house and share the generated data. Additionally, we generate thousands of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and proliferating T cells for functional studies. The TMM biobank serves as an indispensable infrastructure for academic, clinical and industrial research to actualize next-generation medicine in Japan.
AB - The Tohoku Medical Megabank biobank (TMM biobank) is the first major population-based biobank established in Japan. The TMM biobank was established based on two population cohorts and is a reconstruction program from the Great East Japan Earthquake and Tsunami of 2011. The biobank stores more than 3.4 million tubes of biospecimens and associated health and analytic data obtained from approximately 150,000 TMM cohort participants between May 2013 and December 2018, and the TMM biobank currently shares high-quality specimens and data. Various biospecimens, including peripheral and cord blood mononuclear cells, buffy coat, plasma, serum, urine, breast milk and saliva have been collected in the TMM biobank. To minimize human error and maintain the quality of data and specimens, we have been utilizing laboratory information management system into various biobank procedures from registration to storage with various automation systems, such as liquid dispensing, DNA extraction and their storage. The biobank procedures for the quality management system (ISO 9001:2015) and information security management system (ISO 27001:2013) are certified by the International Organization for Standardization. The quality of our biobank samples fulfills the pre-analytical requirements for researchers conducting nextgeneration whole genome sequencing, DNA array analyses, proteomics, metabolomics, etc. We established analytical centers to conduct standard genomic and multiomic analyses in-house and share the generated data. Additionally, we generate thousands of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and proliferating T cells for functional studies. The TMM biobank serves as an indispensable infrastructure for academic, clinical and industrial research to actualize next-generation medicine in Japan.
KW - Biobank
KW - Business continuity planning
KW - ISO
KW - Integrated biobank
KW - Population-based cohort study
UR - http://www.scopus.com/inward/record.url?scp=85066926301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066926301&partnerID=8YFLogxK
U2 - 10.1620/tjem.248.45
DO - 10.1620/tjem.248.45
M3 - Article
C2 - 31130587
AN - SCOPUS:85066926301
VL - 248
SP - 45
EP - 55
JO - Tohoku Journal of Experimental Medicine
JF - Tohoku Journal of Experimental Medicine
SN - 0040-8727
IS - 1
ER -